Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. - AlzForum Alzheimer Research Paper of the Week


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Papers of the Week

Annotation

	John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, Raine CS, Brosnan CF. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med. 2002 Oct;8(10):1115-21. PubMed Abstract

	Comments on Paper and Primary News

	Primary News: Notch Pathway Implicated in Multiple Sclerosis Comment by: Chris Exley
	Submitted 29 June 2002 \| Permalink	Posted 29 June 2002
	The two recent papers published in Science showing an apparent connection between A beta and tau pathologies in transgenic mice models are interesting. However, neither paper reports the effect of a positive control. In both cases a combination of two possible stressors has resulted in a final pathology that is greater than would be expected from the sum of these stressors. However, this is nothing new or even unexpected. It would be new if the resultant pathology could only be reproduced using this combination of stressors. This does not appear to have been tested. The possibility that the observed effects might be explained as a non-specific interaction between 2 co-occurring stressors would explain the lack of similarity of the resulting pathology with that observed in AD. Just a thought. View all comments by Chris Exley

Submit a Comment on this Paper

Cast your vote and/or make a comment on this paper.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password	Minimum of 8 characters
*Confirm Password
Stay signed in?

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.

REAGENTS/MATERIAL:

Western Blot analysis was performed using goat anti-human jagged 1 antibody from Santa Cruz at 1:500 dilution.

For immunohistochemical staining on postmortem tissues the antibodies used were monoclonal anti-Notch 1, 1:200 (Labvision), polyclonal rabbit anti-Hes5, 1:2000 (Chemicon), monoclonal anti-GFAP 1:100 (Dako), polyclonal rabbit anti-S100beta, 1:50 (Dako), monoclonal 04, 1:50 (Chemicon), polyclonal rabbit anti-NG2 1:50 (Chemicon), monoclonal anti-PDGFRalpha,1:25 (R&D Systems) and monoclonal anti-TGFb1, 1:50 (Chemicon). Development was with biotinylated secondary antibodies and standard ABC protocol (Vector Labs) using either DAB or nitroblue tetrazolium for color staining.

Immunocytochemistry on astrocyte cultures used the same anti-jagged1 antibody as above at a 1:500 dilution. For Oligodendrocyte-3T3 cell cocultures monoclonal anti-MBP, 1:100 (Chemicon) or polyclonal anti-CNPase, 1:500 (gift of F.A.McMorris) were used, followed with biotinylated secondary antibodies and developed with ABC method and DAB.